30% Weight Loss! Retatrutide Challenges Weight Loss Surgery. ADA Scientific Sessions 2026
In a Phase 3 clinical trial, an experimental obesity drug just produced the most dramatic weight loss results ever recorded for this class of medication, and at the highest dose, nearly half of participants lost 30 percent or more of their body weight. The Downsized opens its eight-part series on the 2026 American Diabetes Association Scientific Sessions with the drug that generated the biggest headline of the conference: retatrutide. Christopher Durham breaks down Eli Lilly's triple agonist, a single molecule built to activate three hormone receptors at once: GIP, GLP-1, and glucagon. The full Phase 3 TRIUMPH-1 data, presented at ADA 2026 in New Orleans by Dr. Ania Jastreboff of Yale, showed average weight loss of 28.3 percent at 80 weeks on the 12 milligram dose, with 45.3 percent of participants losing 30 percent or more, and no sign of the curve flattening even at two years. The episode also covers TRANSCEND-T2D-1, Lilly's companion trial in people with type 2 diabetes, where the 12 milligram dose produced 16.8 percent average weight loss along with major A1C improvements, including a meaningful share of participants reaching normoglycemic levels entirely. The episode doesn't stop at the headline numbers. It covers the full safety picture, including the GI side effects familiar to anyone on tirzepatide or semaglutide, the dysesthesia signal unique to retatrutide's glucagon component, and the realistic regulatory timeline, with Lilly targeting an FDA filing in late 2026 and approval not expected before late 2027 at the earliest. This is patient-perspective coverage from two people who have lived this treatment themselves. Christopher and Laraine Durham have been on tirzepatide since September 2023, and together have lost more than 150 pounds. Next episode: CagriSema and Novo Nordisk's REIMAGINE data. +++++++++++++++++++++++++++++++++++++++ Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2026: https://thedownsized.org/downsized-at... DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: / @thedownsized FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 Breakthrough Weight Loss 01:12 2026 ADA Scientific Sessions Series 02:44 Why Retatrutide Matters 03:53 Triple Agonist Explained 05:43 TRIUMPH 1 06:43 Triumph 1 Trial Setup 07:38 Record Weight Loss Results 10:48 Beyond Weight Loss Benefits 12:56 Diabetes Trial Transcend T2D-1 16:27 Side Effects and Dysthesia 20:28 Approval Timeline and Access 22:41 Big Unknown Cardiovascular Outcomes 23:40 Key Takeaways and Next Episode

Next Ozempic? Retatrutide's Unknown Side Effect (Pathologist Explains)

Doctor Explains How to Make GLPs 10x More Effective

The Most Exciting Month of Medical Breakthroughs in Years | Plain English

We Gained 13 lbs in 10 Days on GLP-1s, and It is Terrifying!

Forget Zepbound: 15 New Obesity Drugs Are Coming

WOW: Robert Reich drops TRUMP DEMENTIA bomb

Your Biggest GLP-1 Weight Loss Questions Answered! DOWNSIZED LIVE!

Eli Lilly CEO: How GLP-1s Will Reshape America

Nancy Guthrie: How Did They Get In, How Did They Get Out? An Investigator's Perspective

Retatrutide Needs Carbohydrates to Work Properly - Dr Trevor Bachmeyer

Trump and Melania’s Weird Bedroom Secrets Exposed | The Daily Beast Podcast

Doctor Explains How to Dose Retatrutide to MAXIMIZE Fat Loss (not what you think)

Peptides: The Science, Uses & Safety | Dr. Abud Bakri

The Ultimate GLP-1 Guide: Weight Loss, Side Effects & Sarcopenia Risk

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

Retatrutide Is Too Good… And That’s The Problem

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Why I Take Low-Dose Tirzepatide (& Not Retatrutide)

146 lbs Down, Now She's Building Muscle | The Real GLP-1 Story

